Cargando…
Intravenous Zoledronate for a Patient with Paget's Disease
Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for t...
Autor principal: | Kim, Ki-Choul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Bone and Mineral Research
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170086/ https://www.ncbi.nlm.nih.gov/pubmed/25247161 http://dx.doi.org/10.11005/jbm.2014.21.3.223 |
Ejemplares similares
-
Use of zoledronic acid in the treatment of Paget’s disease
por: Seton, Margaret, et al.
Publicado: (2007) -
Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report
por: Panteliou, Eleftheria, et al.
Publicado: (2011) -
Spinal Paget's disease with bilevel cord compression and ischemic non‐compressive myelopathy treated with zoledronic acid
por: Feki, Afef, et al.
Publicado: (2022) -
Treatment of Transient Osteoporosis of the Hip with Intravenous Zoledronate - A Case Report -
por: Seok, Hyun, et al.
Publicado: (2011) -
Response to Zoledronic Acid in Patients with Active Paget's Disease of Bone: A Retrospective Study
por: Durgia, Harsh, et al.
Publicado: (2019)